サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1533935

血友病Bの世界市場

Hemophilia B

出版日
ページ情報
英文 188 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.12円
血友病Bの世界市場
出版日: 2024年08月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 188 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

血友病Bの世界市場は2030年までに64億米ドルに到達

2023年に38億米ドルと推定される血友病Bの世界市場は、分析期間2023-2030年にCAGR 7.8%で成長し、2030年には64億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである中等症は、CAGR 7.7%を記録し、分析期間終了時には27億米ドルに達すると予測されます。軽度重症度疾患セグメントの成長率は、分析期間中CAGR 8.8%と推定されます。

米国市場は9億8,910万米ドルと推定、中国はCAGR7.5%で成長予測

米国の血友病B市場は2023年に9億8,910万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年の分析期間においてCAGR 7.5%で推移し、2030年には10億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.2%と6.7%と予測されています。欧州では、ドイツがCAGR約6.3%で成長すると予測されています。

世界の血友病B市場動向と促進要因まとめ

クリスマス病としても知られる血友病Bは、血液凝固に不可欠なタンパク質である第IX因子の欠乏によって引き起こされる稀な遺伝性出血性疾患です。この疾患はX連鎖性劣性遺伝のため主に男性に発症し、女性は通常保因者です。血友病Bの重症度は様々で、症状は軽度から重度の出血エピソードまであり、しばしば怪我や手術が引き金となります。関節や筋肉への自然出血は一般的な合併症であり、適切に管理されなければ疼痛、腫脹、および長期的な関節損傷を引き起こします。診断は第IX因子活性を測定する血液検査によって確定され、遺伝子検査によって保因者を同定し、家族計画の決定に役立てることができます。治療には通常、遺伝子組換え血液凝固第IX因子製剤または血漿由来血液凝固第IX因子製剤を定期的に注入し、出血エピソードを予防・制御することで、罹患者のQOLを大幅に改善します。

医学研究の進歩は、第Ⅸ因子製剤の管理と理解を著しく向上させました。遺伝子治療は、血液凝固第IX因子遺伝子の機能的コピーを肝臓に送り、そこで必要な血液凝固因子を産生させることにより、1回限りの治癒を目指す有望な治療法として登場しました。初期の臨床試験では有望な結果が得られており、患者は持続的なレベルの第IX因子活性を獲得し、出血エピソードが大幅に減少しました。さらに、投与回数が少なくて済む半減期が延長された血液凝固第IX因子製剤が開発され、治療レジメンの利便性とアドヒアランスが向上しました。これらの技術革新は、診断技術の向上や包括的なケアプログラムとともに、血友病B管理の状況を一変させ、個人がより活動的で充実した生活を送ることを可能にしています。

血友病B治療市場の成長は、いくつかの要因によって牽引されています。遺伝子治療や半減期延長凝固因子製剤などの技術の進歩により、より効果的で便利な治療法が提供されています。血友病Bの有病率の増加は、認知度や診断率の向上と相まって、治療を求める患者層を拡大しています。また、新興国におけるヘルスケアインフラの改善や専門医療へのアクセスも市場成長に寄与しています。さらに、患者支援団体や教育イニシアティブは、早期診断と治療のアドヒアランスを促進する上で重要な役割を果たしています。個人の遺伝子プロファイルに合わせて治療を行う個別化医療へのシフトも、治療の有効性と安全性を高める重要な促進要因となっています。製薬企業が研究開発に投資する中、新規治療薬のパイプラインは増加の一途をたどっており、血友病Bの管理における更なる進歩が期待されています。

調査対象企業の例（全53件）

  • Bayer AG
  • Be Biopharma, Inc.
  • Centessa Pharmaceuticals Plc
  • CSL
  • Freeline Therapeutics
  • Grifols USA, LLC
  • Intellia Therapeutics, Inc.
  • LFB Biotechnologies
  • Medexus Pharma, Inc.（IXINITY）
  • novoMEDLINK
  • Pfizer, Inc.
  • Spark Therapeutics, Inc.
  • Swedish Orphan Biovitrum AB（Sobi）
  • Takeda Pharmaceutical Company
  • uniQure N.V.;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP27103

Global Hemophilia B Market to Reach US$6.4 Billion by 2030

The global market for Hemophilia B estimated at US$3.8 Billion in the year 2023, is expected to reach US$6.4 Billion by 2030, growing at a CAGR of 7.8% over the analysis period 2023-2030. Moderate Severity Disease, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Mild Severity Disease segment is estimated at 8.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$989.1 Million While China is Forecast to Grow at 7.5% CAGR

The Hemophilia B market in the U.S. is estimated at US$989.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 7.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.2% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.3% CAGR.

Global Hemophilia B Market - Key Trends and Drivers Summarized

Hemophilia B, also known as Christmas disease, is a rare genetic bleeding disorder caused by a deficiency of factor IX, a protein essential for blood clotting. This condition primarily affects males due to its X-linked recessive inheritance pattern, with females typically being carriers. Hemophilia B can vary in severity, with symptoms ranging from mild to severe bleeding episodes, often triggered by injuries or surgeries. Spontaneous bleeding into joints and muscles is a common complication, leading to pain, swelling, and long-term joint damage if not properly managed. The diagnosis is confirmed through blood tests that measure factor IX activity, and genetic testing can identify carriers and inform family planning decisions. Treatment usually involves regular infusions of recombinant or plasma-derived factor IX concentrates to prevent and control bleeding episodes, greatly improving the quality of life for those affected.

Advancements in medical research have significantly improved the management and understanding of Hemophilia B. Gene therapy has emerged as a promising treatment option, aiming to provide a one-time cure by delivering functional copies of the factor IX gene to the liver, where it can produce the necessary clotting factor. Early clinical trials have shown encouraging results, with patients achieving sustained levels of factor IX activity and a substantial reduction in bleeding episodes. Additionally, extended half-life factor IX products, which require less frequent dosing, have been developed, offering greater convenience and adherence to treatment regimens. These innovations, along with enhanced diagnostic techniques and comprehensive care programs, are transforming the landscape of Hemophilia B management, enabling individuals to lead more active and fulfilling lives.

The growth in the Hemophilia B treatment market is driven by several factors. Technological advancements, such as gene therapy and extended half-life clotting factor products, are providing more effective and convenient treatment options. The increasing prevalence of Hemophilia B, coupled with greater awareness and diagnosis rates, is expanding the patient pool seeking treatment. Improved healthcare infrastructure and access to specialized care in emerging economies are also contributing to market growth. Furthermore, patient advocacy groups and educational initiatives are playing a crucial role in promoting early diagnosis and treatment adherence. The shift towards personalized medicine, where treatments are tailored to individual genetic profiles, is another key driver, enhancing the efficacy and safety of therapies. As pharmaceutical companies invest in research and development, the pipeline of novel therapies continues to grow, promising further advancements in the management of Hemophilia B.

Select Competitors (Total 53 Featured) -

  • Bayer AG
  • Be Biopharma, Inc.
  • Centessa Pharmaceuticals Plc
  • CSL
  • Freeline Therapeutics
  • Grifols USA, LLC
  • Intellia Therapeutics, Inc.
  • LFB Biotechnologies
  • Medexus Pharma, Inc. (IXINITY )
  • novoMEDLINK
  • Pfizer, Inc.
  • Spark Therapeutics, Inc.
  • Swedish Orphan Biovitrum AB (Sobi)
  • Takeda Pharmaceutical Company
  • uniQure N.V.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Hemophilia B - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Breakthroughs in Gene Therapy for Hemophilia B Gains Ground
    • Global Spending on Healthcare Infrastructure Improves Accessibility to Factor IX Products
    • Development of Extended Half-life Coagulation Factors Expand Treatment Options
    • Personalized Approaches to the Treatment of Hemophilia B Gains Momentum
    • Aging Population with Hemophilia, a Key Demographic Driver of Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hemophilia B Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hemophilia B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Hemophilia B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Hemophilia B by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Moderate Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Moderate Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Moderate Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Mild Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Mild Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Mild Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Severe Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Severe Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Severe Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for On-Demand Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for On-Demand Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for On-Demand Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Prophylaxis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
  • JAPAN
    • Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
  • CHINA
    • Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
  • EUROPE
    • Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Hemophilia B by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Hemophilia B by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Hemophilia B by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
  • FRANCE
    • Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
  • GERMANY
    • Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Rest of Europe 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Europe 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Asia-Pacific 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Asia-Pacific 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of World 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of World 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030

IV. COMPETITION